🩹
Healthcare & Biotech Supply Chain & Quality Failure 2001 - 2019

PIP 硅胶植入物丑闻 (PIP Implants):当原料成本压力遇到薄弱的认证环节,谁会先出问题?

认证是门槛而不是保障,一旦供应商自己决定原料,门槛就形同虚设

PIP 硅胶植入物丑闻 (PIP Implants):巅峰期法国植入物制造商,产品为乳房填充用硅胶假体,通过低成本策略进入欧洲与南美多国市场,出货量巨大;终局是被发现使用未获批的工业级硅胶替代医疗级原料,产品在全球范围被召回,数十万使用者被建议移除,创始人最终被判刑。

See the patterns
公开报道整理 待核查 Figures as of 2019 0 sources What do these mean?

How to read this bar

This bar states plainly what we know and what we have checked, so you can judge it yourself.

· Review status: “pending” means no editor has checked it against the sources yet; “checked” means key facts match the sources.

· Figures as of: the year the numbers are current to; later changes are out of scope.

· Sources: listed one by one at the bottom of the page. “Primary” means official filings, annual reports or regulator documents.

· Corrections: every change and its basis is published — nothing is edited silently.

Editorial policy → Editorial policy: the full inclusion rules, verification process, AI disclosure and correction promise.

No English translation for this case yet — showing the stored original.
Peak valuation

法国植入物制造商,产品为乳房填充用硅胶假体,通过低成本策略进入欧洲与南美多国市场,出货量巨大

Final cost

被发现使用未获批的工业级硅胶替代医疗级原料,产品在全球范围被召回,数十万使用者被建议移除,创始人最终被判刑

Attribution votes

2,498 votes cast

Community output

1 plans · 1 insights

Sponsored
把你亲历的失败写进来

投稿会先进入待审,通过后才进入公开目录和站点地图。

Root Causes Consensus Poll

Vote for the primary fatal error that caused this enterprise to collapse.

产品技术

用工业原料替代医疗级原料

成本压力直接改变了产品的安全基础,且未被申报

822 votes (33%)
外部合规

认证机构对原料变更缺少核查

关键变更不申报即无法被发现,认证退化为一次性门槛

690 votes (28%)
产品技术

破裂率异常缺少早期预警

不良反应依靠个别医生报告汇总,缺少系统性监测

559 votes (22%)
战略

企业以成本与销量为唯一竞争策略

低价格依赖压低原料成本,风险被转移到使用者身上

427 votes (17%)